文献速递肿瘤 PET/CT核素与放射性配体治疗

不可手术III期NSCLC放化疗后残留代谢肿瘤体积的差异预后作用

Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-10-19

本研究分析了56例不可手术III期NSCLC患者完成标准放化疗后18F-FDG PET/CT测量的残留代谢肿瘤体积(rMTV)的预后价值,其中21例后续接受免疫检查点抑制剂(ICI)。结果显示较小rMTV与更长PFS、LPFS和OS相关,尤其在单纯放化疗亚组中;而接受放化疗+ICI的患者结局显著改善且独立于rMTV。

要点

  • 较小rMTV与更长PFS、LPFS和OS显著相关,尤其在未接受ICI的放化疗患者中。
  • 放化疗+ICI患者较单纯放化疗患者PFS、LPFS和OS均显著延长。
  • 在放化疗+ICI亚组中,rMTV与PFS、LPFS、OS均无显著关联。

核心结论

  • 在III期NSCLC中,较小的残留代谢肿瘤体积与更优的临床结局高度相关,尤其是在未接受免疫检查点抑制剂的放化疗患者中。
  • 接受放化疗+免疫检查点抑制剂的患者结局显著优于单纯放化疗患者,且其临床结局独立于残留代谢肿瘤体积。
  • 因此,即使残留代谢肿瘤体积较大的患者也可能从免疫检查点抑制剂治疗中获益。

研究设计与样本

  • 回顾性分析56例不可手术III期NSCLC患者(16例女性,中位年龄65.0岁),完成标准放化疗后行18F-FDG PET/CT。
  • 残留代谢肿瘤体积采用标准阈值(肝脏SUVmean + 2×标准差)勾画,21/56例患者后续接受免疫检查点抑制剂治疗。
  • 以中位数4.3 ml二分法将患者分为体积亚组(rMTV ≤ 4.3 ml vs. > 4.3 ml),分析rMTV、临床特征及ICI应用与PFS、LPFS、OS的相关性。

主要发现

  • 总体中位随访52.0个月,较小rMTV组中位PFS为29.3 vs. 10.5个月(p=0.015),LPFS为49.9 vs. 13.5个月(p=0.001),OS为63.0 vs. 23.0个月(p=0.003)。
  • 放化疗+ICI组较单纯放化疗组中位PFS为29.3 vs. 11.2个月(p=0.034),LPFS未达到 vs. 14.0个月(p=0.016),OS未达到 vs. 25.2个月(p=0.007)。
  • 单纯放化疗亚组中,较小rMTV与更长中位PFS(33.5 vs. 8.6个月,p=0.001)、LPFS(49.9 vs. 10.1个月,p=0.001)和OS(63.0 vs. 16.3个月,p=0.004)相关。
  • 放化疗+ICI亚组中,rMTV与PFS、LPFS、OS均无显著关联(p均>0.05)。
  • 上述发现在后续多因素分析中得到证实。

关键数值与推荐

  • 残留代谢肿瘤体积勾画阈值:肝脏SUVmean + 2×标准差。
  • 体积亚组二分界值:中位数4.3 ml(rMTV ≤ 4.3 ml vs. > 4.3 ml)。

临床怎么用

  • 对于不可手术III期NSCLC完成放化疗后,可通过18F-FDG PET/CT测量的rMTV进行预后分层。
  • 较小rMTV提示单纯放化疗后预后较好,而rMTV较大者仍可能从免疫检查点抑制剂治疗中获益。
  • 放化疗+ICI患者的结局独立于rMTV,提示ICI可能削弱rMTV的预后意义。

局限性

  • 样本量较小(56例),其中仅21例接受ICI,亚组分析效力有限。
  • 为单中心回顾性分析,中位随访52.0个月。
  • rMTV勾画采用单一固定阈值,未比较其他阈值或勾画方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The PET-derived metabolic tumor volume (MTV) is an independent prognosticator in non-small cell lung cancer (NSCLC) patients. We analyzed the prognostic value of residual MTV (rMTV) after completion of chemoradiotherapy (CRT) in inoperable stage III NSCLC patients with and without immune checkpoint inhibition (ICI). METHODS: Fifty-six inoperable stage III NSCLC patients (16 female, median 65.0 years) underwent 18F-FDG PET/CT after completion of standard CRT. rMTV was delineated on 18F-FDG PET/CT using a standard threshold (liver SUVmean + 2 × standard deviation). 21/56 patients underwent additional ICI (CRT-IO, 21/56 patients) thereafter. Patients were divided in volumetric subgroups using median split dichotomization (MTV ≤ 4.3 ml vs. > 4.3 ml). rMTV, clinical features, and ICI-application were correlated with clinical outcome parameters (progression-free survival (PFS), local PFS (LPFS), and overall survival (OS). RESULTS: Overall, median follow-up was 52.0 months. Smaller rMTV was associated with longer median PFS (29.3 vs. 10.5 months, p = 0.015), LPFS (49.9 vs. 13.5 months, p = 0.001), and OS (63.0 vs. 23.0 months, p = 0.003). CRT-IO patients compared to CRT patients showed significantly longer median PFS (29.3 vs. 11.2 months, p = 0.034), LPFS (median not reached vs. 14.0 months, p = 0.016), and OS (median not reached vs. 25.2 months, p = 0.007). In the CRT subgroup, smaller rMTV was associated with longer median PFS (33.5 vs. 8.6 months, p = 0.001), LPFS (49.9 vs. 10.1 months, p = 0.001), and OS (63.0 vs. 16.3 months, p = 0.004). In the CRT-IO subgroup, neither PFS, LPFS, nor OS were associated with MTV (p > 0.05 each). The findings were confirmed in subsequent multivariate analyses. CONCLUSION: In stage III NSCLC, smaller rMTV is highly associated with superior clinical outcome, especially in patients undergoing CRT without ICI. Patients with CRT-IO show significantly improved outcome compared to CRT patients. Of note, clinical outcome in CRT-IO patients is independent of residual MTV. Hence, even patients with large rMTV might profit from ICI despite extensive tumor load.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Unterrainer M, Taugner J, Käsmann L, et al. Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition. Eur J Nucl Med Mol Imaging. 2021. PMID: 34664091. doi:10.1007/s00259-021-05584-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。